Power Law company profile

POINT Biopharma

Biotech & Life Sciences · Toronto, Canada · Founded 2019 · IPO 2020 Unicorn

Developing next-generation radioligand therapies for the treatment of cancer

Valuation

$1.00B

Market cap · 2026

Revenue

$227M

Latest reported FY

EBITDA

$127M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where POINT Biopharma has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States71.8%

🇨🇦 Canada27.4%

🇮🇪 Ireland2.1%

3 countries shown

Patent intelligence

$417k patent portfolio · 7 active families

Estimated portfolio value

$417k

0.04% of market cap · 849.1× smaller than top peer Reata Pharmaceuticals ($354M)

7 active patent families

Where POINT Biopharma innovates Medicinal chemistryCombinatorial chemistryPharmacologyPharmaceutical drugOrganic chemistry

Where POINT Biopharma concentrates vs peers

Each axis is a top-10 topic across POINT Biopharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about POINT Biopharma

An AI-synthesized read of the highest-engagement posts about POINT Biopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See POINT Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles